India Pharma Faces US Tariff Threat: Export Crisis Looms

US President Donald Trump has unveiled a new tariff strategy targeting generic medicines, proposing a 100% duty on imports starting August 2028. This duty is set to escalate to 200% by August 2029, unless manufacturing operations are relocated to the United States.

This policy presents a substantial challenge to India’s $30-billion pharmaceutical industry. India currently supplies approximately 47% of generic prescriptions dispensed in the US, making it a critical supplier.

Implications for Indian Pharma

The country also accounts for 38% of total US pharma exports from India, valued at $10 billion. While the immediate financial impact on Indian drugmakers is expected to be limited due to a two-year exemption, future costs are significant.

Companies anticipate incurring costs related to supply-chain realignment. Adjustments to manufacturing plans and customer negotiations are also expected.

Industry experts caution that these steep tariffs could render most generic exports commercially unviable. They also anticipate a significant squeeze on profit margins for Indian companies.

Key Financial Considerations

Concerns exist that these tariffs could lead to higher prices for low-cost essential medicines for American patients. There is also an increased risk of supply disruptions, particularly in therapeutic areas already prone to shortages.

The two-year tariff-free window offers Indian exporters time to re-evaluate their supply chains. Investment strategies will also need reconsideration.

A stronger local production footprint in the US may become necessary to mitigate the economic impact of the proposed 100% and 200% tariffs. This could mean substantial new capital expenditure.

Industry Outlook and Policy Context

Major Indian pharmaceutical companies with significant US market revenue include Sun Pharma, Dr Reddy’s Labs, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences. These companies derive 35-50% of their revenue from the US market.

Analysts view this proposal primarily as a negotiating tactic. Its implementation is deferred beyond the next US election cycle, adding a layer of political uncertainty.

Reshoring manufacturing is a complex, costly, and time-consuming process. It may not be economically viable for many products, challenging the practicality of the tariff’s condition.

These tariffs contradict the intent of the Hatch-Waxman framework, which originally aimed to reduce drug prices through increased generic competition. This policy shift could fundamentally alter the landscape for affordable medicines in the US.